Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

A strong finish to the week
Fri, 14 Aug Closing

The benchmark BSE-Sensex reclaimed the 28,000-mark and the NSE-Nifty was trading above 8,500 level as the Indian stock markets finished in positive terrain after fall in Chinese Yuan slowed down and inflation plunged to historic low of -4.05% in July, from -2.40% in June. The BSE-Sensex closed higher by about 518 points, while the NSE-Nifty ended higher by about 163 points. Mid and smallcap stocks closed the day on a firm note as well with the S&P BSE Midcap and S&P BSE Smallcap indices ending higher by 2.3% and 1.8% respectively. Gains were largely seen in realty, banking and auto stocks.

Asian stock markets finished mixed as of the most recent closing prices. The Shanghai Composite gained 0.27%, while the Nikkei 225 led the Hang Seng lower. They fell 0.37% and 0.12% respectively. European stocks gained in early trade. The rupee was trading weak by 12 paise at 65.12 in the post-noon session.

Shares of Crompton Greaves surged more than 2% after it was reported that the company bagged Rs 3 bn worth of orders from Power Grid, the largest transmission utility in India, for supply, erection, testing and commissioning of power transfers at various substations across India. The orders include 765 kV transformers for the Chittorgarh and Ajmer Substations, both part of the Green Energy Corridor. This is an initiative by the Government of India to facilitate evacuation of renewable energy into the national grid. The company has also bagged orders for the supply of 400kV transfomers and reactors to Power Grid. The transformers and reactor will be commissioned at power grid substations in Kunta, Madhigiri, Narendra, Silchar, Mondola, Manesar, Panchhkula and Damoh.

Stocks from healthcare sector surged 2% in today's trade with IPCA Labs and Glenmark Pharma being the top gainers. However, Divi's Laboratories and Dr Reddy's Lab traded below the dotted line. According to a leading financial daily, Natco Pharma has received approval from Foreign Investment Promotion Board (FIPB) for increase of Foreign Investment Limit from 24% to 31.5% of the paid up equity share capital of the company. FIPB has also approved issue and allotment of eligible securities to Qualified Institutional Buyers (QIBs) up to Rs 4.5 bn. The scrip of Natco Pharma ended the trading day up by 1.3% on the BSE.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "A strong finish to the week". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.